PharMerica Corporation Investor Alert: Investigation over potential Wrongdoing
An investigation for current long-term investors in shares of PharMerica Corporation over potential wrongdoing by certain officers and directors was announced and NYSE-PMC stockholders should contact the Shareholders Foundation.
Investors who are current long-term stockholder of shares of PharMerica Corporation have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain PharMerica officers and directors breached their fiduciary duties and caused damage to the company and its shareholders by, among other things, failing to implement adequate internal controls.
PharMerica Corporation reported that its annual Total Revenue declined from over $2.08 billion in 2011 to over $1.83 billion in 2012 and that its respective Net Income declined from $23.40 million to $2.90 million.
On August 9, 2013 the Department of Justice announced that it had filed a suit against PharMerica Corporation for allegedly violating the False Claims Act and the Controlled Substances Act by dispensing controlled substances without valid prescriptions and causing claims for illegally dispensed drugs to be submitted for reimbursement under the Medicare program.
Shares of PharMerica Corporation declined from $15.27 per share in August 5, 2013, to $13.30 per share on August 15, 2013.
Those who purchased shares of PharMerica Corporation , have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
Shareholders Foundation, Inc.